[1] | Drew, B., Dixon, A., Dixon, J., 2007, Obesity management, update on orlistat, Vasc Health Risk Manag, 3: 817-821. |
[2] | Pi., Sunyer, FX., 2002, The obesity epidemic: Pathophysiology and consequences of obesity. Obes Res, 10:97S- 104S. |
[3] | National Task Force on the Prevention and Treatment of Obesity 2000, Overweight, obesity and health risk, Arch Int Med, 160:898-904. |
[4] | Andrej, D., Biljana, G., Rok, D., Petra, K., JulIjana, K., 2010, Pharmaceutical Nanotechnology Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition, Int J Pharm, 396: 149-155. |
[5] | Rump, P., Verstappen, F., Gerver, W., 2002, Body composition and cardiorespiratory fitness indicators in prepubescent boys and girls. Int J Sports Med, 23: 50-54. |
[6] | Padwel, R., Majumdar, S., 2007, Drug treatments for obesity: orlistat sibutramine, and rimonabant, Lancet, 369: 71-77. |
[7] | Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--The evidence report: National institutes of health. Obes Res. 1998;6: 51S-209S. |
[8] | L., L., Ioannides, Demos, J., Proietto, and J., J., McNeil, 2005, “Pharmacotherapy for obesity,” Drugs, vol. 65, no. 10, pp. 1391– 1418. |
[9] | Mirja, T., Robert, B., Aila, R., Irma, S., Marjo, T., Kari, T., Hannele, Y., 2004, Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr, 79: 22-30. |
[10] | Heck, A., Yanovski, J., Calis, K., 2000 Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy, 20: 270-279. |
[11] | Calderón, Guzmán, D.1, et.., 2011 Proc. West. Pharmacol. Soc. 54: 72-76. |
[12] | B. M., Geigera, M., Haburcaka, N. M., Avenab,c., M. C., Moyerc, B. G., Hoebelc, and E. N., Pothosa, 2009, Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience, 159(4): 1193–1199. |
[13] | Pugh, T.D., Klopp, R.G., Weindruch, R., 1999, Controlling caloric consumption: Protocols for rodents and rhesus monkeys. Neurobiol. Aging Mar-Apr;20(2):157-165. Samir Nairooz, Suzi H. Ibrahim, Sahar M.M.Omar and Mohammad Affan, Egypt. J. Histol. Vol. 33, No. 4, Dec., 2010: 635 – 648. |
[14] | Altunkaynak, B.Z., 2005, Effects of high fat diet induced obesity on female rat livers (a histochemical study). Eur.J.Gen.Med.; 2(3): 100-109. |
[15] | Sasaki, T., Matsy, S., Sonae, A., 1972, Effect of acetic acid concentration on the colour reaction in the O-toluidine boric acid method for blood glucose estimation. Rinsh. Kagaku. 1: 346–353. |
[16] | Wilson, M. A., Miles, L.E.M., 1977, Radioimmunoassay of insulin in Hand book of Radio immunoassay G. E, Abraham .ed M. Inc. New York, p275. |
[17] | Palacio, A., Lopez, M., Perez-Bravo, F., Monkeberg, F.and Schlesinger, L., 2002, Leptin levels are associated with immune response in malnourished infants. J Clin Endocrinol Metab, 87:3040-3046. |
[18] | Kostener, C. M., 1977, Enzymatic determination of cholesterol high density lipoprotein fraction prepared by polyanion precipitation. J. Clin. Chem, 22:695. |
[19] | Fruchart, G.G., 1982, LDL-Cholesterol determination after separation of low density lipoprotein. Rev. Fr. Des. Laboratories, 103: 7:117. |
[20] | Reitman, S., Frankel, S., 1957, Determination of glutamate pyruvat transaminase and glutamate oxaloacetate transaminase. Amer. J. Clin. Path., 28:56-63. |
[21] | Flohe, L., Gunzler, W.A., 1984, Analysis of glutathione peroxidase. Methods Enzymol, 105: 114–121. |
[22] | Ohkawa, H., Ohishi, N., Yagik, 1979, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction, Anal Biochem , 9535. |
[23] | Calberg, I., Mannerviek, B., 1975, Glutathione reductase level in rat brain, J Biol Chem, 250 (1975) 5475. |
[24] | Balistreri, W., Shaw, L., 1987, Liver function. In: Tietz NW ed. Fundamentals of Clinical Chemistry. W.B. Saunders Company, Philadelphia, pp. 729-760. |
[25] | Tsuzuki, W., U.E., A., Nagao, A., Endo, M., Abe, M., 2004, Inhibitory effect of lysophosphatidylcholine on pancreatic lipase-mediated hydrolysis in lipid emulsion. Biochim Biophys Acta, 1684: 1-7. |
[26] | Navarro, M.A., Carpintero, R., Acin, S., Arbones, Mainar, J.M., Calleja, L., Carnicer, R., Surra, J.C., Guzman, Garcia, M.A., Gonzalez, Ramon, N., Iturralde, M., Lampreave, F., Pineiro, A., Osada, J., 2005, Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine, 31: 52-63. |
[27] | Samy, Eleawa, M.D., Hussein, F., Sakr2, M.D, Effect of exercise and orlistat therapy in rat model of obesity induced with high fat diet. (Cat. No. ab100773 and ab120231, respectively) were purchased from Abcam Biochemicals, USA. |
[28] | Artimage, G.Y., Berry, W.G., 1987, Statistical Methods. 7th Ed. Ames, Iowa Stata University Press, 39-63. |
[29] | National Institutes of Health. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. Obes Res 1998;6(2): 51S-209S. |
[30] | Wickelgren, I., 1998, Obesity: How big a problem? Science, 280:1364–1367. |
[31] | Sjostrom, L., Rissanen, A., Andersen, T., 1998, Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352:167–173. |
[32] | David, S. W., 2003, Pharmacological therapy of obesity: Past, present, and future. J. Clinical Endocrinology & Metabolism, 88 (6): 2462-2469. |
[33] | Pi., Sunyer, F.X.,1996, A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin. Ther., 18:1006–1035. |
[34] | Mittendorfer, B., Ostlund, R. J., Patterson, B., Klein, S., 2001, Orlistat inhibits dietary cholesterol absorption. Obes. Res., 9:599-604. |
[35] | Asler, I., Zehl, M., Kovaci, F., 2007, Mass spectrometric evidence of covalently-bound tetrahydrolipstatin at the catalytic serine of Streptomyces rimosus lipase. Biochim Biophys Acta, 1770: 163-170. |
[36] | Guerciolini, R., 1997, Mode of action of orlistat. Int. J. Obes. Relat. Metab. Disord., 21(Suppl 3): S12-S23. |
[37] | Rossner, S., Sjostrom, L., Noack, R.., Meinders, A.E., Noseda, G., 2000, Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity; European Orlistat Obesity Study Group. Obes. Res., 8: 49-61. |
[38] | Han, L., Kimura, Y., Kawashima, M., Takaku, T., Hayashi, T., Okuda, H., 2001, Antiobesity effects in rodents of dietary teasaponin, a lipase inhibitor. Int J Obesity Relat Metabol Dis, 25: 1459-1464. |
[39] | Sharma, N., Vinay, S., Sung, S., 2005, Screening of some medicinal plants for anti-lipase activity. J Ethnopharmacol, 97: 453-456. |
[40] | Steven, B., Heymsfield, S., Karen, M., Segal, R., Jonathan, M., Charles, P., 2000, Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med., 160:1321-1326. |
[41] | Hafkamp, A., Havinga, R., Sinaasappel, M., Oude, E., Verkade, H., 2003, Highly effective enteral treatment of unconjugated hyperbilirubinemia in Gunn rats. Gastroenterology, 124: 28. |
[42] | Yesilbursa, D., Serdar, Z., Serdar, A., Sarac, M., Coskun, S., Jali, C., 2005, Lipid peroxides in obese patients and effect of weight loss with orlistat on lipid peroxides level. Int J Obes Relat Metab Disord, 29: 142-145. |
[43] | Kaynar, H., Meral, M., Turhan, H., Keles, M., Celik, G. and Akcay, F., 2005, Glutathione peroxidase, glutathione- stransferasse, catalase, xanthine oxidase, Cu–Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients withsmall cell and non-small cell lung cancer. Cancer Letters, 227:133–139. |
[44] | Meister, A., 1988, Glutathione metabolism and its selective modification. The Journal of Biological Chemistry, 263, 17205–17208. |
[45] | Haslam, D.W., James, W.P., 2005, Obesity. Lancet, 366 (9492): 1197–209. |
[46] | Hamann, A., Matthaei, S., 1996, Regulation of energy balance by leptin. Exp. Clin. Endocrinol. Diabetes, 104 (4): 293–300. |
[47] | Faggioni, R., Moser, A., Feingold, K.R., Grunfeld, C., 2000, Reduced leptin levels in starvation increase susceptibility to endotoxic shock. Am J Pathol, 156:1781-1787. |
[48] | Lopez, I.P., Milagro, F.I., Marti, A, Moreno, Aliaga, M.J., Martinez, J., A., De, Miguel, C., 2005, Highfat feeding period affects gene expression in rat white adipose tissue. Mol. Cell. Biochem, 275(1-2): 109-115. |
[49] | Tschöp, M., Weyer, C., Tataranni, P.A., Devanarayan, V., Ravussin, E., Heiman, M.L., 2001, Circulating ghrelin levels are decreased in human obesity. Diabetes, Apr; 50(4): 707-709. |